BAXTER INTERNATIONAL INC is expected to release its Q3 2026 10-Q filing on October 28, 2026. Last quarter: In Q2 FY2026, Baxter International reported a 5.3% YoY revenue increase to $2.96B and a 38.5% surge in net income to $126M, supported by segment realignments and $75M in tariff refund credits.
EPS Estimate
$0.54
Revenue Estimate
$2.89B
Analyst consensus from Finnhub. Actual results posted within minutes of the SEC filing on the BAX page.
Drawn from management commentary in the Q2 2026 10-Q:
Following the January 2025 sale of its Kidney Care business (Vantive) for $3.2B in after-tax proceeds, Baxter implemented a new operating model reorganized into two primary reportable segments: Medical Products & Therapies ($2.08B sales, +7% YoY) and Healthcare Systems & Technologies ($801M sales, +4% YoY).
Baxter maintained its voluntary hold on shipments and installations of the Novum IQ Large Volume Pump in the U.S. and Canada following Class I recall classifications by the FDA, expecting no meaningful sales from the product while the hold remains in effect.
Cost of goods sold in Q2 FY2026 benefited from $75M in tariff refunds related to court rulings invalidating IEEPA tariffs, partially offsetting inflationary supply chain pressure and ongoing Section 301 tariff costs.
Revenue
$2.96B
+5.34% YoY
EPS (Diluted)
$0.24
+33.33% YoY
Gross Margin
34.9%
-0.4 pts YoY
Operating Income
$217M
+13.61% YoY
Add BAX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.